Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.49 |
| ▸ | CA2 | P00918 | 12/20 | 0.49 |
| ▸ | CA9 | Q16790 | 11/20 | 0.49 |
| ▸ | CA12 | O43570 | 7/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | CA3 | P07451 | 2/20 | 0.49 |
| ▸ | CA6 | P23280 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 4/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215271 | 1.00 | CA1 (0.49) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1929782 | 1.00 | CA1 (0.49) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7814060 | 0.89 | CA1 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL8487400 | 0.89 | CA1 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7807198 | 0.88 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL7807200 | 0.88 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL7810988 | 0.86 | PTGS1 (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7807280 | 0.86 | CA1 (0.49) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7802258 | 0.86 | CA1 (0.49) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7802166 | 0.86 | PTGS1 (0.48) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539169-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| EP-1505962-A2 | MONOTHERAPY FOR THE TREATMENT OF PARKINSON'S DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1499315-A1 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITORS AND THALIDOMIDE FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | claimed |
| US-20040063752-A1 | Such as N-(2-cyclohexyloxynitrophenyl)methane sulfonamide | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | claimed |
| US-20040044028-A1 | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | claimed |
| US-20040006100-A1 | Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S) | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | claimed |
| WO-2003101380-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | claimed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| WO-2003092691-A1 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITORS AND THALIDOMIDE FOR THE TREATMENT OF NEOPLASIA | PHARMACIA COPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| WO-2003088959-A2 | TREATMENT OF PARKINSON'S DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | claimed |
| US-6180651-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | BRISTOL-MYERS SQUIBB | 2001-01-30 | — | — | US | claimed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| US-5972950-A | ANTIINFLAMMATORY AND ANALGESIC AGENT | LABORATORIES UPSA (FR) | 1999-10-26 | — | — | US | disclosed |
| WO-1998015528-A1 | NOVEL DIARYLMETHYLENE DERIVATIVES, METHOD FOR PREPARING AND THERAPEUTIC USES THEREOF | LABORATOIRES UPSA (FR) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | CA1 4702/4885CA2 2938/4885CA9 2739/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | CA1 1780/4885CA2 700/4885CA9 1475/4885 |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | SMN1; SMN2, PTGS2, PTGES2 | CA1 911/4885CA2 339/4885CA9 2461/4885 |
| US-20040044028-A1 | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer | PTGES3, PTGER3, PTGES2 | CA1 2265/4885CA2 643/4885CA9 1347/4885 |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | CA1 397/4885CA2 218/4885CA9 741/4885 |
| US-20040006100-A1 | Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S) | PTGS2, PTGES2, PTGS1 | CA1 1437/4885CA2 695/4885CA9 1929/4885 |
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PTGES2, PTGS2, PTGER2 | CA1 1028/4885CA2 308/4885CA9 1642/4885 |
| US-20040063752-A1 | Such as N-(2-cyclohexyloxynitrophenyl)methane sulfonamide | SMN1; SMN2, PTGS2, PTGES2 | CA1 635/4885CA2 265/4885CA9 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.